|
| AURKA is a potential target for multiple myeloma therapy |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/APJBG.2017032017021 |
| KeyWord:Multiple myeloma, AURKA, MLN8237 |
| Author | Institution |
| Ting Lu |
School of Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China |
| Chunyan Gu |
School of Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China |
|
| Hits: 2562 |
| Download times: 2295 |
| Abstract: |
| Multiple myeloma (MM) is an incurable disease with the second most frequent hematopoietic malignancy. In this study, we found that the expression of Aurora kinase A (AURKA) was significantly increased in patients with high-risk multiple myeloma, especially in proliferation subgroups. MLN8237, a small molecule AURKA inhibitor, inhibited MM cell proliferation by inducing cell apoptosis and injury. Thus, we speculate MLN8237 is a potential therapeutic agent for MM and AURKA may be a potential target for MM treatment. |
| Close |
|
|
|
